The prospective adalimumab biosimilar CinnoRA was shown in a recently published phase 3 trial to be comparable to AbbVie’s innovator biological treatment Humira in terms of safety and efficacy in adult patients with active rheumatoid arthritis.
The prospective adalimumab biosimilar CinnoRA (under development by CinnaGen Co, based in Alborz, Iran) was shown in a recently published phase 3 trial to be comparable to AbbVie’s innovator biological treatment Humira in terms of safety and efficacy in adult patients with active rheumatoid arthritis (RA). The study, by Ahmadreza Jamshidi, MD, professor of internal medicine, Rheumatology Research Center at Tehran University of Medical Sciences, Tehran, Iran, and colleagues, was published online in Arthritis Research & Therapy and registered with the Iranian Registry of Clinical Trials.
This randomized, double-blind, active-controlled, noninferiority trial recruited 136 adult patients with active RA to receive 40 mg subcutaneous injections of either CinnoRA or Humira every other week while receiving methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over a 24-week period. Physical examinations—including vital sign evaluations and laboratory testing—were conducted at baseline, 12 weeks, and 24 weeks. The 68 patients randomized to each arm of the study had comparable demographic information, lab results, and disease characteristics at baseline; 64 patients in each group completed the 24-week study period.
The study’s primary endpoint was the proportion of patients achieving a moderate or good disease activity score of 28 (based on the European League Against Rheumatism [EULAR] response rate) in terms of joints-erythrocyte sedimentation rate (DAS28-ESR). Secondary endpoints were the proportion of patients achieving American College of Rheumatology (ACR) criteria for 20% (ACR20), 50% (ACR50), and 70% (ACR70) responses (measured as improvement in tender and swollen joint counts; patient assessments of pain, global disease activity, and physical function; physician global assessment of disease activity; and acute phase reactant), a disability index of health assessment questionnaire (HAQ), and safety.
The proportion of patients achieving good and moderate EULAR responses in the CinnoRA group was noninferior to the Humira group at 12 and 24 weeks, based on both intention-to-treat and per-protocol populations (all P values >.05). There were no significant differences in the proportion of patients achieving ACR20, ACR50, and ACR70 responses in the CinnoRA and Humira groups (all P values >.05).
The difference in HAQ scores and safety outcome measures between treatment arms was not statistically significant, the researchers noted. Four patients withdrew from the CinnoRA group due to adverse drug reactions (ADRs; n = 2), a positive tuberculin test (n = 1), and poor compliance (n = 1). Similarly, 4 patients left the Humira group because of ADRs (n = 3) and poor compliance (n = 1). The researchers did not notice any significant difference in the incidence of injection site reactions as the most prevalent adverse events between treatment arms.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.